These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15921858)

  • 1. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma.
    Wu T
    Biochim Biophys Acta; 2005 Jul; 1755(2):135-50. PubMed ID: 15921858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells.
    Wu T; Han C; Lunz JG; Michalopoulos G; Shelhamer JH; Demetris AJ
    Hepatology; 2002 Aug; 36(2):363-73. PubMed ID: 12143044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 in hepatocellular carcinoma.
    Wu T
    Cancer Treat Rev; 2006 Feb; 32(1):28-44. PubMed ID: 16337744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells.
    Nzeako UC; Guicciardi ME; Yoon JH; Bronk SF; Gores GJ
    Hepatology; 2002 Mar; 35(3):552-9. PubMed ID: 11870367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions.
    Endo K; Yoon BI; Pairojkul C; Demetris AJ; Sirica AE
    Hepatology; 2002 Aug; 36(2):439-50. PubMed ID: 12143054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids.
    Lim K; Han C; Xu L; Isse K; Demetris AJ; Wu T
    Cancer Res; 2008 Jan; 68(2):553-60. PubMed ID: 18199552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.
    Sirica AE
    Hepatology; 2005 Jan; 41(1):5-15. PubMed ID: 15690474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies.
    Sirica AE; Lai GH; Zhang Z
    J Gastroenterol Hepatol; 2001 Apr; 16(4):363-72. PubMed ID: 11357901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells.
    Yoon JH; Gwak GY; Lee HS; Bronk SF; Werneburg NW; Gores GJ
    J Hepatol; 2004 Nov; 41(5):808-14. PubMed ID: 15519654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
    Kashfi K; Rigas B
    Biochem Pharmacol; 2005 Oct; 70(7):969-86. PubMed ID: 15949789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
    Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
    Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.
    Sirica AE
    World J Gastroenterol; 2008 Dec; 14(46):7033-58. PubMed ID: 19084911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
    Chun KS; Surh YJ
    Biochem Pharmacol; 2004 Sep; 68(6):1089-100. PubMed ID: 15313405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.
    Hayashi N; Yamamoto H; Hiraoka N; Dono K; Ito Y; Okami J; Kondo M; Nagano H; Umeshita K; Sakon M; Matsuura N; Nakamori S; Monden M
    Hepatology; 2001 Oct; 34(4 Pt 1):638-50. PubMed ID: 11584358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets.
    Sirica AE; Lai GH; Endo K; Zhang Z; Yoon BI
    Semin Liver Dis; 2002 Aug; 22(3):303-13. PubMed ID: 12360423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of cyclo-oxygenase-2.
    Stack E; DuBois RN
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):787-800. PubMed ID: 11566041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of cyclooxygenase-1 and -2 in extra-hepatic cholangiocarcinoma.
    Wu GS; Wang JH; Liu ZR; Zou SQ
    Hepatobiliary Pancreat Dis Int; 2002 Aug; 1(3):429-33. PubMed ID: 14607721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma.
    Chariyalertsak S; Sirikulchayanonta V; Mayer D; Kopp-Schneider A; Fürstenberger G; Marks F; Müller-Decker K
    Gut; 2001 Jan; 48(1):80-6. PubMed ID: 11115827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.